XM does not provide services to residents of the United States of America.
T
T

Teva


News

US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug

US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug Lower court found Norwich generic infringes Salix patents Alvogen has Xifaxan generic deals with Teva, Sun, Sandoz By Blake Brittain WASHINGTON, Nov 18 (Reuters) - The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's BHC.TO blockbuster diarrhea drug Xifaxan.
T

Teva Pharm CEO says will work productively with Trump administration

Teva Pharm CEO says will work productively with Trump administration JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical Industries TEVA.TA expects to work productively with the incoming Trump administration in the United States, chief executive Richard Francis said on Wednesday. "Our job, as always, is to work productively with any administration, and we've shown we can do that, and we will absolutely do that," Francis told Reuters after the Israeli drugmaker issued strong third-quarter results.
T

Teva Pharma's listed shares up after lifting 2024 forecast, upbeat Q3 results

BUZZ-Teva Pharma's US-listed shares up after lifting 2024 forecast, upbeat Q3 results ** U.S.-listed shares TEVA.N of Israel-based Teva Pharmaceutical rise 2.1% to $19.16 premarket ** Co raises its 2024 rev. and earnings forecast after beating Q3 profit forecasts, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease ** Raises 2024 rev.
T

Teva Pharmaceutical raises 2024 outlook as Q3 profit beats estimates

UPDATE 2-Teva Pharmaceutical sees more growth in 2025 after strong Q3 Adds CEO comments, financial details, company background, paragraphs 2-3, 7-9 and 14 Teva raises 2024 revenue and earnings guidance after strong Q3 results CEO Richard Francis expects continued growth in 2025, including biosimilar business Teva fined over $500 million by European Commission, plans to appeal By Steven Scheer JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical Industries TEVA.TA raised its 2024 revenue and earnings
T

Teva Pharmaceutical third-quarter profit, revenue top estimates

Teva Pharmaceutical third-quarter profit, revenue top estimates JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical Industries TEVA.TA reported a larger than expected rise in third-quarter profit, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease. The world's largest generic drugmaker said on Wednesday it earned 69 cents per diluted share excluding one-time items in the July-September quarter, up from 60 cents per share a year earlier.
T

Teva Reports Q3 2024 Results, Driven By Generics And Innovative Portfolio, Raises 2024 Outlook

BRIEF-Teva Reports Q3 2024 Results, Driven By Generics And Innovative Portfolio, Raises 2024 Outlook Nov 6 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA ANNOUNCES STRONG FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2024, LED BY GENERICS PERFORMANCE AND INNOVATIVE PORTFOLIO GROWTH; RAISES 2024 FINANCIAL OUTLOOK INCLUDING ON REVENUES, A
T

Teva Pharmaceutical Industries Ltd <TEVA.N> expected to post earnings of 66 cents a share - Earnings Preview

Teva Pharmaceutical Industries Ltd expected to post earnings of 66 cents a share - Earnings Preview Teva Pharmaceutical Industries Ltd TEVA.N , TEVA.K is expected to show a rise in quarterly revenue when it reports results on November 6 for the period ending September 30 2024 The Tel Aviv-yafo Israel-based company is expected to report a 7.0% increase in revenue to $4.119 billion from $3.85 billion a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
T

Financial Times - Nov 1

PRESS DIGEST- Financial Times - Nov 1 Nov 1 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Rival creditor group offers Thames Water emergency loan at lower rate - British aerospace pioneer Reaction Engines collapses into administration - GB News fined 100,000 stg in first financial sanction by Ofcom - EU fines world's largest generic drugmaker Teva for hindering competition Overview -
B
T

Drugmakers Apotex, Heritage to pay $49 mln to resolve states' price-fixing claims

Drugmakers Apotex, Heritage to pay $49 mln to resolve states' price-fixing claims By Mike Scarcella Oct 31 (Reuters) - Generic drugmakers Apotex and Heritage Pharmaceuticals have agreed to pay nearly $50 million to settle claims by Connecticut and other states that accused them of conspiring to artificially inflate prices. Heritage, a subsidiary of India’s Emcure Pharmaceuticals, and Apotex said they will cooperate with the states in continuing litigation against dozens of other drugmakers acc
P
T

Teva hit with $503 mln EU antitrust fine for disparaging rival product

UPDATE 1-Teva hit with $503 mln EU antitrust fine for disparaging rival product Adds response from Teva in paragraph 2 and paragraphs 6-8, fresh Vestager comments, details By Sudip Kar-Gupta BRUSSELS, Oct 31 (Reuters) - Teva TEVA.TA , the world's largest generic drugmaker, was hit on Thursday with a 462.6 million euro ($503 million) EU antitrust fine for abusing its dominant position to delay competition to its blockbuster multiple sclerosis medicine Copaxone .
T

Teva fined $503 mln by EU for disparaging rival product

Teva fined $503 mln by EU for disparaging rival product BRUSSELS, Oct 31 (Reuters) - The European Commission has fined Teva TEVA.TA , the world's largest generic drugmaker, 462.6 million euros ($503 million) for abusing its dominant position to delay competition to its blockbuster multiple sclerosis medicine Copaxone, confirming a Reuters exclusive .
T

Amicus Therapeutics Enters License Agreement With Teva Pharmaceuticals

BRIEF-Amicus Therapeutics Enters License Agreement With Teva Pharmaceuticals Oct 17 (Reuters) - Amicus Therapeutics Inc FOLD.O : AMICUS THERAPEUTICS ANNOUNCES SETTLEMENT OF GALAFOLD® (MIGALASTAT) PATENT LITIGATION WITH TEVA AMICUS THERAPEUTICS INC - ENTERS LICENSE AGREEMENT WITH TEVA PHARMACEUTICALS AMICUS THERAPEUTICS INC - TEVA TO MARKET GENERIC GALAFOLD IN U.S.
T

Wall Street Journal - Oct 11

PRESS DIGEST-Wall Street Journal - Oct 11 Oct 11 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - China-owned social-media platform TikTok is laying off employees as part of a revamp of its content-moderation operations. It plans to invest $2 billion globally in trust and safety initiatives in 2024, aiming to improve efficacy.
N
T

Teva to pay $450 million to resolve US kickback, price-fixing cases

UPDATE 1-Teva to pay $450 million to resolve US kickback, price-fixing cases Adds details on settlement, background of case throughout By Nate Raymond BOSTON, Oct 10 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA has agreed to pay $450 million to resolve allegations it used charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay kickbacks to boost sales of its multiple sclerosis drug Copaxone and conspired to fix prices for generic drugs.
R
T

Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says

Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says WASHINGTON, Oct 10 (Reuters) - New Jersey-based drugmaker Teva has agreed to pay $450 million to resolve allegations that it violated an anti-kickback statute and the False Claims Act, the U.S. Justice department said in a statement on Thursday. "Kickbacks designed to induce referrals or purchases of healthcare goods or services distort physician and patient decision-making, thwart competition and bypass controls put
T

Teva Prolia Biosimilar Candidate Is Accepted For Review By U.S. FDA And EU EMA

BRIEF-Teva Prolia Biosimilar Candidate Is Accepted For Review By U.S. FDA And EU EMA Oct 8 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA PROLIA® (DENOSUMAB) BIOSIMILAR CANDIDATE IS ACCEPTED FOR REVIEW BY U.S. FDA AND EU EMA TEVA PHARMACEUTICAL INDUSTRIES LTD - FDA AND EMA DECISIONS EXPECTED IN 2H 2025 Source text for Eikon: ID:nGN
T

Abu Dhabi's ADNOC to buy German chemicals firm Covestro for $16 bln

UPDATE 6-Abu Dhabi's ADNOC to buy German chemicals firm Covestro for $16 bln ADNOC to pay 62 euros per Covestro share, take on 3 bln in debt To buy additional 1.2 bln euros worth of new shares in Covestro Covestro shares jump 3.7% to a three-year high Deal could fuel debate over foreign takeovers of German firms Adds Covestro supervisory board's advisers in paragraph 26 By Ludwig Burger and Yousef Saba BERLIN/DUBAI Oct 1 (Reuters) - Abu Dhabi's ADNOC has struck a deal to buy German chemicals mak
B
C
G
N
O
T
U
V

Copycat drugmakers will be low-key obesity winners

BREAKINGVIEWS-Copycat drugmakers will be low-key obesity winners The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, Sept 25 (Reuters Breakingviews) - Generic drug makers are getting ready to take a bite out of the booming weight loss market. Firms like Teva Pharmaceutical TEVA.TA and Sandoz SDZ.S have started to launch the first copycats from the class of drugs which include Novo Nordisk's NOVOb.CO hugely successful Ozempic and Wegovy
T

Teva Says Tev-‘749 Meets Primary Endpoint In Phase 3 Study

BRIEF-Teva Says Tev-‘749 Meets Primary Endpoint In Phase 3 Study Sept 21 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA PRESENTS NEW PHASE 3 EFFICACY, SAFETY AND TOLERABILITY DATA FROM SOLARIS TRIAL EVALUATING TEV-‘749 (OLANZAPINE) AS A ONCE-MONTHLY SUBCUTANEOUS LONG-ACTING INJECTABLE FOR ADULT PATIENTS DIAGNOSED WITH SCHIZOPHREN
T

Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports

Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports Sept 17 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations, Bloomberg News reported on Tuesday citing a company executive . Part of 2022's Inflation Reduction Act allows Medicare to negotiate prices for prescription drugs that had been particularly expensive for the federal health program w
P
T



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.